Cargando…
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study
OBJECTIVE: Interferon-free regimens of direct-acting antiviral agents have improved the treatment response for chronic hepatitis C virus (HCV) infection, and improvement in the serum albumin level during interferon-free therapy has been reported. The aim of this study was to identify the factors tha...
Autores principales: | Kawano, Akira, Shigematsu, Hirohisa, Miki, Koichiro, Ichiki, Yasunori, Morita, Chie, Yanagita, Kimihiko, Takahashi, Kazuhiro, Dohmen, Kazufumi, Nomura, Hideyuki, Ishibashi, Hiromi, Shimoda, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028685/ https://www.ncbi.nlm.nih.gov/pubmed/29321441 http://dx.doi.org/10.2169/internalmedicine.9857-17 |
Ejemplares similares
-
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020) -
Development of Hepatocellular Carcinoma in Patients Aged 75–84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2020) -
Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2021) -
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan
por: Igarashi, Ataru, et al.
Publicado: (2019) -
Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study
por: Ogawa, Eiichi, et al.
Publicado: (2022)